Presenting today at the World Conference on Lung Cancer: LCRF grantee Dr. William Feng.
Read more about his research at LCRF.org/FengUpdate.
@lcrf.org
@lcrf.orgPresenting today at the World Conference on Lung Cancer: LCRF grantee Dr. William Feng.
Read more about his research at LCRF.org/FengUpdate.
@lcrf.orgOur grateful thanks to Catalyst Pharmaceuticals for sponsoring the Free to Breathe Chicago Walk! #FreeToBreathe #LungCancer #ThankYou
@lungcancereurope.bsky.socialBetter #lungcancer diagnosis needs collaboration across the whole pathway.
At #WCLC26, our VP presented collaborative work with Lung Cancer Policy Network work drawing on evidence, 12 expert interviews and contributions from multidisciplinary members. #LCSM
@lcrf.orgAmong those presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF Scientific Advisory Board members Dr. Christine Lovly and Dr. Karen Reckamp; and LCRF grantees Dr. William Feng and Dr. Jamie Chaft.
@lcrf.orgAmong those presenting today at #WCLC26 in Seoul, South Korea: LCRF Education + Engagement Committee members Drs. Stephen Liu and Eric Singhi; LCRF Team Science grantee Dr. Elaine Shum; and LCRF Together Chicago panelist Dr. Jyoti Patel.
#LungCancer @stephenvliu.bsky.social @lungoncdoc.bsky.social
@lungcancereurope.bsky.social🧠 Phase 3 MAVERICK results at #WCLC26 could change care for small cell #lungcancer.
MRI surveillance alone protected cognitive outcomes vs adding preventive brain radiotherapy, with no significant diff in survival so far.
If confirmed, this could spare some people with #SCLC unnecessary treatment.
@lcrf.orgThe #LungCancer community will come out strong at the Free to Breathe Kansas City Walk – come and connect with other caring people! Join us Saturday, Sept 26 at Longview Lake Shelter #13. Sign up at lcrf.org/kc.
@lcrf.orgPresenting today at #WCLC26 in Seoul: LCRF grantees Drs. Hilary Robbins (twice!) and Xiuning Le; Education + Engagement Committee members Drs. Stephen Liu, Eric Singhi, & Narjust Florez; & Scientific Advisory Board member Dr. Roy Herbst.
#LungCancer @lungoncdoc.bsky.social @stephenvliu.bsky.social
@jamasurgery.comSingle-encounter #AugmentedReality localization was noninferior to CT-guided localization for #LungCancer resection and was associated with reduced radiation, lower pain, and shorter workflow times. ja.ma/4hdC9dW
@cancers-mdpi.bsky.socialLive from #WCLC26! 📸 Our team is all set at Booth #706. Drop by to connect, share insights, and discuss the latest in lung cancer research. We’d love to meet you! 💞
#IASLC #LungCancer #WCLC2026 @iaslc.bsky.social
@lungcancereurope.bsky.socialOur President joined speakers from across the lung cancer community at #WCLC2026 today for From Evidence to Action: Practical Skills for Engaging Policymakers on Earlier #LungCancer Detection.
She spoke about handling objections to
screening & how advocates can respond when concerns are raised.
@drjkyl.bsky.socialA phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC
@tamedoncol.bsky.social
@journals.sagepub.com
@oncoalert.bsky.socialThe 🚨 OncoAlert TOP 10 — #WCLC26 🌐
👉Advanced #SCLC & #Mesothelioma 🇰🇷
We’re kicking off our OncoAlert TOP 10 for #WCLC26 with a focus on Advanced Small Cell #LungCancer ( #SCLC ) and Mesothelioma🫁
@lcrf.orgOur grateful thanks to R&R for sponsoring the Free to Breathe Kansas City Walk! #FreeToBreathe #LungCancer #ThankYou
@glcc01.bsky.socialThat’s a wrap on the GLCC Members’ Meeting.
Our shared workplan for the next 12 months is now agreed, and we’ll be posting updates here — and on our new website coming soon.
Grateful to everyone who strengthens this global #lungcancer advocacy network.
See you at #WCLC26 and in Denver next year.
@vcclibrary.bsky.socialInduction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell #LungCancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. www.thelancet.com/journals/lan...
@vcclibrary.bsky.socialCeralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell #LungCancer: Two cohorts of the phase II platform National Lung Matrix Trial. @velindrecc.bsky.social aacrjournals.org/clincancerre...
@alkpositiveuk.bsky.socialOur 2025 Impact Report looks back at everything our ALK+ #lungcancer community helped make possible, from our biggest national conference yet and growing regional meet-ups to new support, trusted information and stronger advocacy for people with ALK+.
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: BTOG 2026 BTOG 2026 Young Researcher of the Year Award presented by Tom Newsom-Davis. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: BTOG 2026 Doctor of the Year Award presented by Tom Newsom-Davis. Full recordings and presentations available to members on our website. #LCSM #lungcancer